This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Search
Skip to Search Results-
Development of traceable Rituximab modified polymeric micelles for active targeting of B-cell Lymphoma
DownloadFall 2017
Abstract B-cell Non-Hodgkin Lymphoma (NHL) accounts for more than 90% of all adult cases of lymphomas and in most cases it is CD20 positive. B-cell NHL is usually treated by combination of conventional chemotherapeutics and the monoclonal antibody against CD20, rituximab. This combination regimen...
-
Fall 2017
Epstein-Barr virus (EBV) is a “kissing disease virus” that has infected more than 95% of the adult human population. It has been associated with diseases such as Acute Infectious Mononucleosis (AIM) and post-transplant lymphoproliferative disorder (PTLD). The kinetics of primary EBV infection has...
-
2010
Sensen, C.W., Goss, G.G., Childs, S.J., Zuccolo, J., Bau, J., Deans, J.P.
Background: The MS4A gene family in humans includes CD20 (MS4A1), FcRb (MS4A2), Htm4 (MS4A3), and at least 13 other syntenic genes encoding membrane proteins, most having characteristic tetraspanning topology. Expression of MS4A genes is variable in tissues throughout the body; however, several...